Immunosuppressant Combined With Pirfenidone in CTD-ILD

Key facts

Sponsor

Qilu Hospital of Shandong University

Principal Investigator

Yang Xiaoyun, Dr.

Qilu Hospital of Shandong University

Intervention

Pirfenidone(drug)

Enrollment

200 enrolled

Eligibility

18-80 years · All sexes

Timeline

2019 – 2025

Study locations (1)

• Qilu Hospital, Jinan, Shandong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07283081
  Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias
  University Hospital, Bordeaux
• RECRUITINGNANCT07254338
  Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension Treatment
  Hospices Civils de Lyon
• RECRUITINGNANCT07301697
  Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy
  University Hospital, Strasbourg, France
• RECRUITINGNANCT07300696
  Functional MRI for Monitoring Progression and Assessing Trends in ILD
  University Hospital Heidelberg
• RECRUITINGPHASE2NCT06053164
  Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
  University of Alberta
• RECRUITINGNCT05819385
  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)
  Boehringer Ingelheim
• RECRUITINGNCT06948942
  Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung Disease
  Gazi University
• RECRUITINGNCT06235645
  dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound
  University Hospital, Tours

See all trials for Interstitial lung disease →